Q-omics provides the consensus-scored DUXAP7 profile across patient tissues and cancer cell-line models. DUXAP7 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, DUXAP7 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, DUXAP7 RNA expression shows 12,331 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, UCEC, and GBM as cancer lineages where DUXAP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUXAP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUXAP7 survival associations across molecular data types. DUXAP7 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUXAP7 RNA expression–survival associations across cancer types. High DUXAP7 expression shows unfavorable associations in MESO, KICH, COAD and LUSC, but favorable associations in LUAD and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for DUXAP7 RNA expression.
This table summarizes DUXAP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DUXAP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUXAP7 shows lower tumor expression in UCEC, THCA, LUSC and COAD. The UCEC box plot shows higher DUXAP7 RNA expression in normal versus tumor tissue (log2 FC = −0.128, t-test p = .012).
This table shows molecular features associated with DUXAP7 in patient tissues and cancer cell lines. In patient samples, DUXAP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
